By Deborah Schoch Marcel Kuttab first sensed something was awry while brushing her teeth a year ago, several months after recovering from Covid-19. Her toothbrush tasted dirty, so she threw it out and got a new one. Then she realized the toothpaste was at fault. Onions and garlic and meat tasted putrid, and coffee smelled like gasoline — all symptoms of the once little-known condition called parosmia that distorts the senses of smell and taste. Dr. Kuttab, 28, who has a pharmacy doctoral degree and works for a drug company in Massachusetts, experimented to figure out what foods she could tolerate. “You can spend a lot of money in grocery stores and land up not using any of it,” she said. The pandemic has put a spotlight on parosmia, spurring research and a host of articles in medical journals. Membership has swelled in existing support groups, and new ones have sprouted. A fast-growing British-based Facebook parosmia group has more than 14,000 members. And parosmia-related ventures are gaining followers, from podcasts to smell training kits. Yet a key question remains unanswered: How long does Covid-linked parosmia last? Scientists have no firm timelines. Of five patients interviewed for this article, all of whom first developed parosmia symptoms in late spring and early summer of last year, none has fully regained normal smell and taste. Brooke Viegut, whose parosmia began in May 2020, worked for an entertainment firm in New York City before theaters were shuttered. She believes she caught Covid in March during a quick business trip to London, and, like many other patients, she lost her sense of smell. Before she regained it completely, parosmia set in, and she could not tolerate garlic, onions or meat. Even broccoli, she said at one point earlier this year, had a chemical smell. She still can’t stomach some foods, but she is growing more optimistic. “A lot of fruits taste more like fruit now instead of soap,” she said. And she recently took a trip without getting seriously nauseous. “So, I’d say that’s progress.” © 2021 The New York Times Company

Keyword: Chemical Senses (Smell & Taste); Neuroimmunology
Link ID: 27857 - Posted: 06.16.2021

Adrienne Matei Asked about the future of Parkinson’s disease in the US, Dr Ray Dorsey says, “We’re on the tip of a very, very large iceberg.” Dorsey, a neurologist at the University of Rochester Medical Center and author of Ending Parkinson’s Disease, believes a Parkinson’s epidemic is on the horizon. Parkinson’s is already the fastest-growing neurological disorder in the world; in the US, the number of people with Parkinson’s has increased 35% the last 10 years, says Dorsey, and “We think over the next 25 years it will double again.” Most cases of Parkinson’s disease are considered idiopathic – they lack a clear cause. Yet researchers increasingly believe that one factor is environmental exposure to trichloroethylene (TCE), a chemical compound used in industrial degreasing, dry-cleaning and household products such as some shoe polishes and carpet cleaners. Advertisement Employers think the pandemic was a time for earnest self-improvement. Screw that | Jessa Crispin To date, the clearest evidence around the risk of TCE to human health is derived from workers who are exposed to the chemical in the work-place. A 2008 peer-reviewed study in the Annals of Neurology, for example, found that TCE is “a risk factor for parkinsonism.” And a 2011 study echoed those results, finding “a six-fold increase in the risk of developing Parkinson’s in individuals exposed in the workplace to trichloroethylene (TCE).” Dr Samuel Goldman of The Parkinson’s Institute in Sunnyvale, California, who co-led the study, which appeared in the Annals of Neurology journal, wrote: “Our study confirms that common environmental contaminants may increase the risk of developing Parkinson’s, which has considerable public health implications.” It was off the back of studies like these that the US Department of Labor issued a guidance on TCE, saying: “The Board recommends [...] exposures to carbon disulfide (CS2) and trichloroethylene (TCE) be presumed to cause, contribute, or aggravate Parkinsonism.” © 2021 Guardian News & Media Limited

Keyword: Parkinsons
Link ID: 27856 - Posted: 06.16.2021

Andrew Anthony David Eagleman, 50, is an American neuroscientist, bestselling author and presenter of the BBC series The Brain, as well as co-founder and chief executive officer of Neosensory, which develops devices for sensory substitution. His area of speciality is brain plasticity, and that is the subject of his new book, Livewired, which examines how experience refashions the brain, and shows that it is a much more adaptable organ than previously thought. For the past half-century or more the brain has been spoken of in terms of a computer. What are the biggest flaws with that particular model? It’s a very seductive comparison. But in fact, what we’re looking at is three pounds of material in our skulls that is essentially a very alien kind of material to us. It doesn’t write down memories, the way we think of a computer doing it. And it is capable of figuring out its own culture and identity and making leaps into the unknown. I’m here in Silicon Valley. Everything we talk about is hardware and software. But what’s happening in the brain is what I call livewire, where you have 86bn neurons, each with 10,000 connections, and they are constantly reconfiguring every second of your life. Even by the time you get to the end of this paragraph, you’ll be a slightly different person than you were at the beginning. In what way does the working of the brain resemble drug dealers in Albuquerque? It’s that the brain can accomplish remarkable things without any top-down control. If a child has half their brain removed in surgery, the functions of the brain will rewire themselves on to the remaining real estate. And so I use this example of drug dealers to point out that if suddenly in Albuquerque, where I happened to grow up, there was a terrific earthquake, and half the territory was lost, the drug dealers would rearrange themselves to control the remaining territory. It’s because each one has competition with his neighbours and they fight over whatever territory exists, as opposed to a top-down council meeting where the territory is distributed. And that’s really the way to understand the brain. It’s made up of billions of neurons, each of which is competing for its own territory. © 2021 Guardian News & Media Limited

Keyword: Development of the Brain; Stroke
Link ID: 27855 - Posted: 06.16.2021

Dr Rocio Camacho Morales A transparent metallic film allowing a viewer to see in the dark could one day turn regular spectacles into night vision googles. The ultra-thin film, made of a semiconductor called gallium arsenide, could also be used to develop compact and flexible infrared sensors, scientists say. Though still a proof of concept, the researchers believe it could eventually be turned into a cheap and lightweight replacement for bulky night-vision goggles, which are used in military, police and security settings. The film was developed by a team of Australian and European researchers, with details published in the journal Advanced Photonics. It works by converting infrared light – which is normally invisible to humans – into light visible to the human eye. The study’s first author, Dr Rocio Camacho Morales of the Australian National University, said the material was hundreds of times thinner than a strand of human hair. The gallium arsenide is arranged in a crystalline structure only several hundred nanometres thick, which allows visible light to pass through it. The film has certain similarities to night vision goggles. Blind man has sight partly restored after pioneering treatment Read more “The way these night vision goggles work [is] they also pick up infrared light,” said Camacho Morales. “This infrared light is converted to electrons and displayed [digitally]. In our case, we’re not doing this.” Instead, the film, which does not require any power source, changes the energy of photons of light passing through it, in what is known as a nonlinear optical process. One likely advantage of this film over existing technologies is weight: bulky helmet-mounted night vision goggles have previously been associated with neck pain in airforce pilots, for example. Photons of infrared light have very low energy, Camacho Morales said, which means that electronic night vision devices can be affected by random fluctuations in signal. To minimise these fluctuations, many infrared imaging devices use cooling systems, sometimes requiring cryogenic temperatures. © 2021 Guardian News & Media Limited

Keyword: Vision
Link ID: 27854 - Posted: 06.16.2021

By Carolyn Wilke Scientists have long sought to prevent sharp memories from dulling with age, but the problem remains stubborn. Now research published in Scientific Reports suggests virtual reality might help older people recall facts and events based on specific details. The study involved 42 healthy older adults from the San Francisco Bay Area. Half spent a dozen hours over four weeks playing a virtual-reality game called Labyrinth; they strapped on headsets and walked in place, roaming virtual neighborhoods while completing errands. The other half, in the control group, used electronic tablets to play games that did not require navigating or recalling details. After 15 sessions, the latter performed roughly the same as before on a long-term memory test based on picking out objects they had seen about an hour earlier. But the Labyrinth players' scores rose, and they were less frequently tricked by objects that resembled ones they had viewed. Those improvements “brought them back up to the level of another group of younger adults who did the same memory tests,” says cognitive neuroscientist Peter Wais of the University of California, San Francisco. He and his colleagues designed the VR game, which they say likely stimulates the hippocampus—a brain area important for long-term memory. The team did not observe improvement on two other tests, which measured autobiographical memory and spatial memory capability. © 2021 Scientific American,

Keyword: Learning & Memory; Alzheimers
Link ID: 27853 - Posted: 06.16.2021

Ed Yong Carl Schoonover and Andrew Fink are confused. As neuroscientists, they know that the brain must be flexible but not too flexible. It must rewire itself in the face of new experiences, but must also consistently represent the features of the external world. How? The relatively simple explanation found in neuroscience textbooks is that specific groups of neurons reliably fire when their owner smells a rose, sees a sunset, or hears a bell. These representations—these patterns of neural firing—presumably stay the same from one moment to the next. But as Schoonover, Fink, and others have found, they sometimes don’t. They change—and to a confusing and unexpected extent. Schoonover, Fink, and their colleagues from Columbia University allowed mice to sniff the same odors over several days and weeks, and recorded the activity of neurons in the rodents’ piriform cortex—a brain region involved in identifying smells. At a given moment, each odor caused a distinctive group of neurons in this region to fire. But as time went on, the makeup of these groups slowly changed. Some neurons stopped responding to the smells; others started. After a month, each group was almost completely different. Put it this way: The neurons that represented the smell of an apple in May and those that represented the same smell in June were as different from each other as those that represent the smells of apples and grass at any one time. This is, of course, just one study, of one brain region, in mice. But other scientists have shown that the same phenomenon, called representational drift, occurs in a variety of brain regions besides the piriform cortex. Its existence is clear; everything else is a mystery. Schoonover and Fink told me that they don’t know why it happens, what it means, how the brain copes, or how much of the brain behaves in this way. How can animals possibly make any lasting sense of the world if their neural responses to that world are constantly in flux? (c) 2021 by The Atlantic Monthly Group

Keyword: Chemical Senses (Smell & Taste)
Link ID: 27852 - Posted: 06.11.2021

By Carl Zimmer Dr. Adam Zeman didn’t give much thought to the mind’s eye until he met someone who didn’t have one. In 2005, the British neurologist saw a patient who said that a minor surgical procedure had taken away his ability to conjure images. Over the 16 years since that first patient, Dr. Zeman and his colleagues have heard from more than 12,000 people who say they don’t have any such mental camera. The scientists estimate that tens of millions of people share the condition, which they’ve named aphantasia, and millions more experience extraordinarily strong mental imagery, called hyperphantasia. In their latest research, Dr. Zeman and his colleagues are gathering clues about how these two conditions arise through changes in the wiring of the brain that join the visual centers to other regions. And they’re beginning to explore how some of that circuitry may conjure other senses, such as sound, in the mind. Eventually, that research might even make it possible to strengthen the mind’s eye — or ear — with magnetic pulses. “This is not a disorder as far as I can see,” said Dr. Zeman, a cognitive scientist at the University of Exeter in Britain. “It’s an intriguing variation in human experience.” The patient who first made Dr. Zeman aware of aphantasia was a retired building surveyor who lost his mind’s eye after minor heart surgery. To protect the patient’s privacy, Dr. Zeman refers to him as M.X. When M.X. thought of people or objects, he did not see them. And yet his visual memories were intact. M.X. could answer factual questions such as whether former Prime Minister Tony Blair has light-colored eyes. (He does.) M.X. could even solve problems that required mentally rotating shapes, even though he could not see them. I came across M.X.’s case study in 2010 and wrote a column about it for Discover magazine. Afterward, I got emails from readers who had the same experience but who differed from M.X. in a remarkable way: They had never had a mind’s eye to begin with. © 2021 The New York Times Company

Keyword: Attention; Vision
Link ID: 27851 - Posted: 06.11.2021

By Emily Underwood In the 1930s, neurosurgeon Wilder Penfield pioneered a daring new kind of cartography. As a stenographer took notes, he delicately touched an electrode to the exposed brains of his awake, consenting patients and asked what they felt as electrical current hit different areas. Penfield wanted to better predict which brain functions would be threatened when surgeons had to remove tumors or chunks of tissue that were triggering epileptic seizures. Stimulating adjacent brain regions, he found, produced sensations in corresponding body parts: hand, forearm, elbow. The result of his mapping was the iconic “homunculus”: a map on the brain’s wrinkled outer layer representing the surface of the body. Penfield then ventured into more mysterious territory. When he probed the insula, a deep fold of cortex, some patients felt nauseated or gassy; others belched or vomited. “My stomach is upset and I smell something like medicine,” one said. Penfield found those visceral signals harder to decipher than the brain’s map of the body’s surface. Brain regions responsible for different internal sensations seemed to overlap. Sensory regions were hard to distinguish from those that sent motor instructions such as telling the intestines to contract. Penfield once asked participants to swallow an electrode to detect changes in gut contractions while he stimulated their brains. But his map of the inner organs was blurry and ambiguous—and stayed that way for most of the next century. Decades later, scientists are starting to unravel how our wet, spongy, slippery organs talk to the brain and how the brain talks back. That two-way communication, known as interoception, encompasses a complex, bodywide system of nerves and hormones. Much recent exploration has focused on the vagus nerve: a massive, meandering network of more than 100,000 fibers that travel from nearly every internal organ to the base of the brain and back again. © 2021 American Association for the Advancement of Science.

Keyword: Learning & Memory; Obesity
Link ID: 27850 - Posted: 06.11.2021

By Pam Belluck and Rebecca Robbins In a powerful statement of disagreement with the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, three scientists have resigned from the independent committee that advised the agency on the treatment. “This might be the worst approval decision that the F.D.A. has made that I can remember,” said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, who submitted his resignation Thursday after six years on the committee. He said the agency’s approval of the drug, aducanumab, which is being marketed as Aduhelm, a monthly intravenous infusion that Biogen has priced at $56,000 per year, was wrong “because of so many different factors, starting from the fact that there’s no good evidence that the drug works.” Two other members of the committee resigned earlier this week, expressing dismay at the approval of the drug despite the committee’s overwhelming rejection of it after reviewing clinical trial data in November. The committee had found that the evidence did not convincingly show that Aduhelm could slow cognitive decline in people in the early stages of the disease — and that the drug could cause potentially serious side effects of brain swelling and brain bleeding. None of the 11 members of the committee considered the drug ready for approval: Ten voted against and one was uncertain. “Approval of a drug that is not effective has serious potential to impair future research into new treatments that may be effective,” said Dr. Joel Perlmutter, a neurologist at Washington University School of Medicine in St. Louis, who was the first to resign from the committee. © 2021 The New York Times Company

Keyword: Alzheimers
Link ID: 27849 - Posted: 06.11.2021

Ian Sample Science editor Regular strenuous exercise raises the risk of developing motor neurone disease (MND) in people who are genetically predisposed to the condition, researchers say. Scientists at the University of Sheffield found a causal relationship between high intensity physical activity and the disorder among those already susceptible to the disease. They believe the work marks a major step towards understanding the link between intense exercise, which may contribute to motor neurone injury in certain people, and the neurodegenerative disease, which affects about 5,000 individuals in the UK. “We have suspected for some time that exercise was a risk factor for MND, but until now this link was considered controversial,” said Dr Johnathan Cooper-Knoc, a neurologist at Sheffield. “This study confirms that in some people, frequent strenuous exercise leads to an increase in the risk of MND.” The life-time risk of developing MND is about 1 in 400, but previous studies have suggested it is six times greater in professional football players compared with the general population. A number of high-profile British sportsmen have shared their experience with MND in recent years, including rugby league’s Rob Burrow, rugby union’s Doddie Weir and the the footballer Stephen Darby. The Sheffield researchers emphasise that the vast majority of people who undertake vigorous exercise do not develop MND, and that their next step is to develop tests that identify people most at risk. © 2021 Guardian News & Media Limited

Keyword: ALS-Lou Gehrig's Disease
Link ID: 27848 - Posted: 06.11.2021

By Anahad O'Connor According to recent studies, the number of people complaining of insomnia skyrocketed during the pandemic, rising from 20 percent of adults last summer to nearly 60 percent in March. If you’re one of those people who’s been plagued by poor sleep, the Well desk is here to help. Recently, we asked our readers to tell us two things: What’s keeping you from getting a good night’s rest? And what are the most pressing questions you would ask a sleep expert? More than 1,200 of you responded. You asked about insomnia, supplements, middle-of-the-night awakenings, snoring bed mates and more. So we collected your most popular questions, brought them to the world’s top sleep experts and shared their answers below. Sometimes I am physically tired but can’t fall asleep. How is that possible? This is what’s known as the tired but wired syndrome. Usually, it’s driven by stress and anxiety. Even if you’re exhausted, a racing mind can activate the “fight or flight” branch of your nervous system, making you alert and unable to fall asleep. “For us to fall asleep and stay asleep, we need to go in the opposite nervous system direction,” said Matthew Walker, a professor of neuroscience and psychology at the University of California, Berkeley, and the author of the best-selling book “Why We Sleep.” “We need to shift over to the calming branch of the nervous system called the parasympathetic nervous system.” © 2021 The New York Times Company

Keyword: Sleep
Link ID: 27847 - Posted: 06.11.2021

By Laurie McGinley The Food and Drug Administration on Monday approved the first Alzheimer’s treatment intended to slow cognitive decline, a move hailed by patients and advocates but sharply criticized by others who argued there was not sufficient evidence that the drug works. The medication, called aducanumab, is the first drug cleared for Alzheimer’s that is designed to alter the course of the disease by slowing the deterioration of brain function — not just to ease symptoms. No Alzheimer’s treatment has been approved since 2003, reflecting the extraordinarily high failure rate of drugs developed for the illness. But in an explicit acknowledgment of the uncertainties about the effectiveness of the drug, the FDA did not grant the medication full approval. Instead, the agency cleared the drug — its brand name will be Aduhelm — based on its ability to reduce clumps of amyloid beta in the brain, a hallmark of the disease. It ordered the drug’s maker, the biotech giant Biogen, to conduct a post-approval study confirming the medicine actually slows cognitive deterioration. If the medication does not provide such a clinical benefit, the FDA’s approval could be withdrawn. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said officials believe it is “reasonably likely” that the reduction in amyloid clumps will confer “important benefits to patients.” Monday’s FDA decision was the most contentious in years and followed prolonged debate among researchers, doctors, patients and advocates about whether the medication works — a consequence of the drug’s complicated history. One of the biggest points of disagreement is whether a reduction in amyloid beta, a sticky compound that many scientists believe damages communication between brain cells and eventually kills them, results in a slowdown in cognitive decline. © 1996-2021 The Washington Post

Keyword: Alzheimers
Link ID: 27846 - Posted: 06.08.2021

By Ben Guarino and Frances Stead Sellers In the coronavirus pandemic’s early weeks, in neuropathology departments around the world, scientists wrestled with a question: Should they cut open the skulls of patients who died of covid-19 and extract their brains? Autopsy staff at Columbia University in New York were hesitant. Sawing into bone creates dust, and the Centers for Disease Control and Prevention had issued a warning about the bodies of covid patients — airborne debris from autopsies could be an infectious hazard. But as more patients were admitted and more began to die, researchers decided to “make all the efforts we could to start collecting the brain tissue,” Columbia neuropathologist Peter D. Canoll said. In March 2020, in an insolation room, the Columbia team extracted a brain from a patient who had died of severe covid-19, the illness caused by the coronavirus. During the next months, they would examine dozens more. Saw met skull elsewhere, too. In Germany, scientists autopsied brains — even though medical authorities recommended against doing that. Researchers were searching the brain for damage — and for the virus itself. At the pandemic’s start, understanding how the virus affected the nervous system was largely a mystery. S. Andrew Josephson, chair of neurology at the University of California at San Francisco and editor in chief of the academic journal JAMA Neurology, said, “We had hundreds of submissions of ‘I saw one case of X.’” It was difficult to understand whether single cases has any relationship to covid at all. Patients reported visual and auditory disturbances, vertigo and tingling sensations, among other perplexing symptoms. Some lost their sense of smell, or their vision became distorted. Weeks or months after the initial onset of symptoms, some remain convinced after even a mild bout of the coronavirus of persistent “brain fog.”

Keyword: Learning & Memory; Attention
Link ID: 27845 - Posted: 06.08.2021

By Jason S. Tsukahara, Alexander P. Burgoyne, Randall W. Engle It has been said that “the eyes are the window to the soul,” but new research suggests that they may be a window to the brain as well. Our pupils respond to more than just the light. They indicate arousal, interest or mental exhaustion. Pupil dilation is even used by the FBI to detect deception. Now work conducted in our laboratory at the Georgia Institute of Technology suggests that baseline pupil size is closely related to individual differences in intelligence. The larger the pupils, the higher the intelligence, as measured by tests of reasoning, attention and memory. In fact, across three studies, we found that the difference in baseline pupil size between people who scored the highest on the cognitive tests and those who scored the lowest was large enough to be detected by the unaided eye. We first uncovered this surprising relationship while studying differences in the amount of mental effort people used to complete memory tasks. We used pupil dilations as an indicator of effort, a technique psychologist Daniel Kahneman popularized in the 1960s and 1970s. When we discovered a relationship between baseline pupil size and intelligence, we weren’t sure if it was real or what it meant. Advertisement Intrigued, we conducted several large-scale studies in which we recruited more than 500 people aged 18 to 35 from the Atlanta community. We measured participants’ pupil size using an eye tracker, a device that captures the reflection of light off the pupil and cornea using a high-powered camera and computer. We measured participants’ pupils at rest while they stared at a blank computer screen for up to four minutes. All the while, the eye tracker was recording. Using the tracker, we then calculated each participant’s average pupil size. © 2021 Scientific American

Keyword: Learning & Memory; Vision
Link ID: 27844 - Posted: 06.08.2021

By Veronique Greenwood The coin is in the illusionist’s left hand, now it’s in the right — or is it? Sleight of hand tricks are old standbys for magicians, street performers and people who’ve had a little too much to drink at parties. Sign up for Science Times: Get stories that capture the wonders of nature, the cosmos and the human body. On humans, the deceptions work pretty well. But it turns out that birds don’t always fall for the same illusions. Researchers in a small study published on Monday in the Proceedings of the National Academy of Sciences reported on Eurasian jays, birds whose intelligence has long been studied by comparative psychologists. The jays were not fooled, at least by tricks that rely on the viewer having certain expectations about how human hands work. However, they were fooled by another kind of trick, perhaps because of how their visual system is built. Magic tricks often play on viewers’ expectations, said Elias Garcia-Pelegrin, a graduate student at the University of Cambridge who is an author of the study. That magic can reveal the viewers’ assumptions suggests that tricks can be a way into understanding how other creatures see the world, he and his colleagues reasoned. Eurasian jays are not newcomers to subterfuge: To thwart thieves while they’re storing food, jays will perform something very like sleight of hand — sleight of beak, if you will — if another jay is watching. They’ll pretend to drop the food in a number of places, so its real location is concealed. © 2021 The New York Times Company

Keyword: Attention; Learning & Memory
Link ID: 27843 - Posted: 06.02.2021

Vincent Acovino A young, red-handed tamarin monkey. Some of these monkeys are changing their vocal call to better communicate with another species of tamarin. Schellhorn/ullstein bild/Getty Images In the Brazilian Amazon, a species of monkey called the pied tamarin is fighting for survival, threatened by habitat loss and urban development. But the critically endangered primate faces another foe: the red-handed tamarin, a more resilient monkey that lives in the same region. They compete for the same resources, and the red-handed tamarin's habitat range is expanding into that of the pied tamarins'. Their clashes sometimes end in violent altercations. But in a recent study, scientists have discovered that the red-handed tamarin is altering its vocal calls to better communicate with the pied tamarin. Tainara Sobroza, an ecology Ph.D. student who worked on the study, says these "territorial calls" are used to warn other species that they are encroaching on their territory, or coming too close to a crucial survival resource. "When this happens, [the two species] usually engage in vocal battles," she says, which sometimes prevent the violent physical battles between the two species. Researchers likened the change in calls to speaking with an accent. "They might need to say 'tomahto' instead of 'tomayto' — that's the kind of nuance in the accent, so that they can really understand each other," Jacob Dunn, a professor of evolutionary biology who worked on the study, told The Guardian. Article continues after sponsor message When analyzing the vocal call of both species, the scientists discovered that the red-handed tamarins new call has a narrower bandwidth and an increased amplitude, making the sound clearer and the duration of the call longer. The result is a call that travels better through the dense forest. © 2021 npr

Keyword: Animal Communication; Language
Link ID: 27842 - Posted: 06.02.2021

By Nayef Al-Rodhan o In Chile, the National Commission for Scientific and Technological Research has begun to debate a “neurorights” bill to be written into the country’s constitution. The world, and most importantly the OECD, UNESCO and the United Nations, should be watching closely. The Chilean bill sets out to protect the right to personal identity, free will, mental privacy, equitable access to technologies that augment human capacities, and the right to protection against bias and discrimination. The landmark bill would be the first of its kind to pioneer a regulatory framework which protects human rights from the manipulation of brain activity. The relatively nascent concept of neurorights follows a number of recent medical innovations, most notably brain-computer interface technology (BCI), which has the potential to revolutionize the field of neuroscience. BCI-based therapy may be useful for poststroke motor rehabilitation and may be a potential method for the accurate detection and treatment of neurological diseases such as Alzheimer’s. Advocates claim there is therefore a moral imperative to use the technology, given the benefits it could bring; others worry about its ethical, moral and societal consequences. Many (mistakenly) see this process as being potentially undermined by premature governance restrictions, or accuse any mention of brake mechanisms as an exaggerated reaction to an unlikely science-fiction scenario. © 2021 Scientific American

Keyword: Robotics; Consciousness
Link ID: 27841 - Posted: 06.02.2021

By Richard Sima An elephant’s trunk is a marvel of biology. Devoid of any joints or bone, the trunk is an appendage made of pure muscle that is capable of both uprooting trees and gingerly plucking individual leaves and also boasts a sense of smell more powerful than a bomb-sniffing dog’s. Elephants use their trunks in a variety of ways. They use it to drink, store and spray water, and they also blow air through it to communicate — their 110-decibel bellows can be heard for miles. “It’s like a muscular multitool,” said Andrew Schulz, a mechanical engineering doctoral student at the Georgia Institute of Technology. In a study published Wednesday in The Journal of the Royal Society Interface, Mr. Schulz and his colleagues reported on how elephants can use their trunks for yet another function: applying suction to grab food, a behavior previously thought to be exclusive to fishes. Despite the ubiquity of elephants in children’s books and nature documentaries, there are numerous gaps in scientific knowledge about the biomechanics of their trunks that the new study helps fill. For example, the most recent detailed account of elephant trunk anatomy is a hand-drawn monograph that was published in 1908, Mr. Schulz said. Contrary to popular belief, the trunk does not act like a straw. “What they do is actually drink water into their trunk and they store it,” Mr. Schulz said. “So the elephant trunk is actually like a trunk.” Mr. Schulz completed his research in the lab of David Hu, which studies how animals move and function with an eye toward applying the discoveries toward human engineering problems. He said one reason elephants’ anatomy is poorly understood is because they are difficult to work with. © 2021 The New York Times Company

Keyword: Evolution; Learning & Memory
Link ID: 27840 - Posted: 06.02.2021

Laurie McGinley When Phil Gutis was diagnosed with early-stage Alzheimer’s disease at 54, he immediately enrolled in a clinical trial for an experimental drug but had little hope of being helped. Over time, though, he started feeling better, his brain less cloudy. “There was just a fogginess I remember having a couple of years ago that I don’t really feel I have now,” said Gutis, who has received monthly infusions of a medication called aducanumab for five years, except for a short interruption. Now, he is hoping others with the disease will have a chance to try the drug. But he is worried that the Food and Drug Administration, which is weighing whether to approve the drug, will reject it, derailing the medication and jeopardizing his ability to get the treatment. “Would my world become fuzzy again?” said Gutis, who lives in New Hope, Pa., with his husband and is a former reporter. “I don’t want to go backward.” By June 7, the FDA is expected to make one of its most important decisions in years: whether to approve the drug for mild cognitive impairment or early-stage dementia caused by Alzheimer’s. It would be the first treatment ever sold to slow the deterioration in brain function caused by the disease, not just to ease symptoms. And it would be the first new Alzheimer’s treatment since 2003. The medication is a monoclonal antibody, a protein made in the laboratory that can bind to substances — in this case, clumps of amyloid beta, a sticky plaque compound that many scientists believe damages communication between brain cells and eventually kills them. The treatment is designed to trigger an immune response that removes the plaques.

Keyword: Alzheimers
Link ID: 27839 - Posted: 06.02.2021

Nicholas Bakalar Many people wear a CPAP machine at night to treat the interrupted breathing of obstructive sleep apnea, a condition that affects an estimated 22 million Americans. But CPAP machines can be noisy, cumbersome and uncomfortable, and many people stop using the devices altogether, which can have dire long-term consequences. Mouth guards may be a more comfortable and easy-to-use alternative for many people with obstructive sleep apnea, according to a new report. The study, published in Laryngoscope, looked at 347 people with sleep apnea who were fitted with a mouth guard by an otolaryngologist. Two-thirds of patients reported they were comfortable wearing the devices, and the devices appeared to be effective in helping to relieve the disordered breathing of obstructive sleep apnea. The lead author of the study, Dr. Guillaume Buiret, head of otolaryngology at Valence Hospital in Valence, France, said that if he had sleep apnea, he would choose an oral appliance first. “It’s easy to tolerate, effective and it costs a lot less than CPAP,” he said. “Thirty to 40 percent of our patients can’t use CPAP, and these patients almost always find the dental appliance helpful. I would recommend it as a first-line treatment” Loud snoring may be the most obvious consequence of sleep apnea, but the condition, if left untreated, can lead to a broad range of complications, including high blood pressure, heart disease, liver dysfunction and Type 2 diabetes. © 2021 The New York Times Company

Keyword: Sleep
Link ID: 27838 - Posted: 06.02.2021